Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis Reaching the Primary Efficacy Endpoint
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment